Abstract
The aim: Evaluation of the effectiveness of the biotherapeutic agent Saccharomyces boulardii in the treatment complex of patients with clinical manifestations of dysbiosis and/or signs of enteric insufficiency refractory to previous therapy, to develop ways for their medical correction. Materials and methods: The study included 209 patients, treated during 2018-2020, grouped into main and the comparison group. The main group was divided into subgroups depending on the nosological form of the underlying disease: surgical – 36, general therapeutic – 58, gynecological – 47 patients. Main group treatment was supplemented with Saccharomyces boulardii for 10-14 days from the first day of inclusion of patients in the observation group. Results: The analysis of motor-evacuation disorders verified flatulence in 89.47%, localized epigastric pain in 22.48%, diarrhea in 55.02%, and constipation in 11.48% of cases. Based on the results of laboratory parameters, an absolute increase in the number of leukocytes in the range from 12.4 ± 1.8 x 109 / l to 14.7 ± 2.8 x 109 / l with a neutrophilic formula shift, bilirubinemia to 54.4 ± 12.2 mmol / l , elevated levels of urea to 14.7 ± 3.9 and creatinine to 0.199 ± 0.07 mmol / L. Conclusions: After completion of the treatment course (main group), a significant (p <0.05) improvement in the general condition (decrease in stool frequency within 1–4 times (2.3 ± 0.28) per day, the absence of rumbling, flatulence and pain in abdomen) in 131 (92.9%) of 141 patients included in the study was stated. Clinical improvement was confirmed by bacteriological studies of copro-culture.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
